weight loss drugs

Novo Nordisk rebrands as ‘Novo’ amid downgrade and pipeline setbacks

Morgan Stanley downgraded Novo Nordisk to Underweight from Equal-weight on September 11, citing a subdued medium-term growth outlook and rising concerns over the approaching patent cliff for semaglutide, the active ingredient behind the blockbuster drugs Ozempic and Wegovy. The bank…

You're all caught up

You've seen all the main stories from the past 2 days.

Cambridge study solves weight loss drug paradox

Scientists at the University of Cambridge have resolved a longstanding puzzle in obesity pharmacology: why both activating and blocking the same receptor can lead to weight loss. The answer, published July 24 in Nature Metabolism, lies in two anatomically separate…